Related Experiment Video
Updated: Aug 5, 2026
09:32
A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
Published on: September 23, 2014
Expression of Thymidylate Synthase in Cancer: A Tissue Microarray Study Involving 17,371 Cancers from 136 Tumor
Florian Lutz1, Lisa Sophie Hannemann1, Seyma Büyücek1
1Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Biomedicines
|July 28, 2026
Summary
Thymidylate synthase (TYMS) is frequently overexpressed in many cancer types, often correlating with aggressive tumor features. This widespread expression highlights its potential as a therapeutic target across diverse malignancies.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Therapeutics
Background:
- Thymidylate synthase (TYMS) is a critical enzyme in DNA synthesis and a recognized therapeutic target.
- Understanding TYMS expression patterns across various cancers is essential for developing targeted therapies.
Purpose of the Study:
- To comprehensively analyze the expression of TYMS across a wide spectrum of human tumors.
- To investigate the correlation between TYMS expression levels and clinicopathological parameters in different cancer types.
Main Methods:
- Immunohistochemistry was employed to assess TYMS expression.
- Analysis was performed on a large-scale tissue microarray comprising 17,371 samples from 136 distinct tumor types.
- Statistical analysis was used to correlate TYMS expression with histopathological features.
Main Results:
- TYMS staining was detected in 42.9% of 15,361 analyzable tumors, with varying intensity.
- High TYMS expression was frequently observed in lymphomas, sarcomas, malignant melanoma, cervical adenocarcinoma, and squamous cell carcinomas.
- Significant associations were found between high TYMS expression and adverse prognostic factors such as advanced tumor stage, high grade, and metastasis in multiple cancer types, including breast, renal cell carcinoma, prostate, and colorectal cancers.
Conclusions:
- TYMS is frequently overexpressed across a broad range of cancer entities.
- TYMS overexpression is often linked to aggressive histopathological features, underscoring its role in tumor progression.
- These findings support TYMS as a relevant therapeutic target in oncology, with potential implications for various cancers.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...